about
Horizon 2020 in Diabetic Kidney Disease: The Clinical Trial Pipeline for Add-On Therapies on Top of Renin Angiotensin System BlockadeAcute kidney injury transcriptomics unveils a relationship between inflammation and ageingModifiable risk factors for increased arterial stiffness in outpatient nephrologyAlbumin-induced apoptosis of tubular cells is modulated by BASP1.Vitamin D and proteinuria: a critical review of molecular bases and clinical experience.Targeting inflammation in diabetic kidney disease: early clinical trials.Peritoneal Dialysis Can Be an Option for Dominant Polycystic Kidney Disease: an Observational Study.Circulating CXCL16 in Diabetic Kidney Disease.Potential Dangers of Serum Urate-Lowering TherapyImpact of Altered Intestinal Microbiota on Chronic Kidney Disease ProgressionPodocyturia: why it may have added value in rare diseasesClarifying the concept of chronic kidney disease for non-nephrologistsAutosomal Dominant Tubulointerstitial Kidney Disease: Clinical Presentation of Patients With ADTKD-UMOD and ADTKD-MUC1Aliskiren and the dual complement inhibition conceptSerum Levels and Removal by Haemodialysis and Haemodiafiltration of Tryptophan-Derived Uremic Toxins in ESKD PatientsExpanding congenital abnormalities of the kidney and urinary tract (CAKUT) genetics: basonuclin 2 (BNC2) and lower urinary tract obstructionDesign and optimization strategies for the development of new drugs that treat chronic kidney diseaseDietary Care for ADPKD Patients: Current Status and Future DirectionsDiagnostic Utility of Exome Sequencing for Kidney DiseaseMYH9-related disease: it does exist, may be more frequent than you think and requires specific therapy
P50
Q26799443-ECDB3076-82E4-4A2A-9594-EA935F15579FQ27023602-480CD2FA-E9A3-446A-9B1D-6898BDFE9F58Q35448958-7FE4C638-F2BE-4037-AE48-28B1E1B9AB14Q36347210-52F67C28-E747-4F97-A1F0-EEF851791CD2Q38148728-84A8E848-875F-428D-A186-51B10783F197Q38857166-F9A9CD5D-9DF9-4DBF-BC30-44AB2C25B65FQ41109994-42658C3B-E3CE-4373-9F06-E0FA978FC7EBQ51465395-8B95F1EF-7EE0-47AD-AECA-8CC537ADE477Q63684329-31474D57-557F-4B64-BBC0-ED5F4B086A3CQ63684332-01D59949-B7B4-4314-A58A-92B013F79D36Q64039944-F3B5B717-17FE-4DDE-AD5F-A7B95E4CB8A3Q64226758-BFAB1AC8-1F3C-4E74-B2C9-62D6F02D0195Q88763062-D3E8F689-E3CE-4FE7-A441-3F1F4CF3EBB7Q89827956-5661B6B5-C9B5-47C7-83B7-70C477FE03C9Q89895574-0A3CBC79-40C0-4B86-8F6F-1192C8B93D0FQ90964061-BDF39CC6-35A1-4654-9499-7B90BDC1D8F7Q91314860-C9723F6F-43EF-472E-B98F-1FAF5FACD8FAQ92128969-7DB30021-53A1-47C5-A83B-0AA945632655Q92217332-1B0DC151-25DA-4E0D-90CF-E82C0E93A36BQ92435104-A1FEC230-02FA-47CB-8581-4F4A20887988
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
M Vanessa Pérez-Gómez
@en
M Vanessa Pérez-Gómez
@nl
type
label
M Vanessa Pérez-Gómez
@en
M Vanessa Pérez-Gómez
@nl
prefLabel
M Vanessa Pérez-Gómez
@en
M Vanessa Pérez-Gómez
@nl
P31
P496
0000-0003-4558-5236